
During a live event, Amy Cummings, MD, discussed a patient case of a 69-year-old man with non–small cell lung cancer and an HER2 exon 20 insertion mutation.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Ready for the challenge? Let’s begin!
Which combination therapy showed superior progression-free survival compared with osimertinib for EGFR-mutated NSCLC?






